Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II imetelstat study in high-risk myelodysplastic syndrome or acute myeloid leukemia after failure of HMA-based therapy
2022-500721-32-01Phase 2Completed
- Sponsor
- GCP-Service International
- Start
- May 2023
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of imetelstat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by GCP-Service International. Primary endpoint: Overall response rate after 4 months. Started May 2023; status: completed.
02
Drugs
imetelstat
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2022-500721-32-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500721-32-01.